Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Miner

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Delaware Journal of Public Health|May 27, 2022
Characteristics and Outcomes of SARS-CoV-2 Infection Among Adults Living With HIV In Delaware:: The Story of a Syndemic During the First 12 Months of the SARS-CoV-2 PandemicAdam K Skrzynski, Brooke L Darmstadter, , et al.
Proceedings of the National Academy of Sciences of the United States of America|April 1, 1971
Isolation of transducing particles of phi-80 bacteriophage that carry different regions of the Escherichia coli genomeR Press, N Glansdorff, P Miner, et al.
Lipids|December 7, 2005
Techniques for delivery of arachidonic acid to Pacific oyster, Crassostrea gigas, spatC Seguineau, P Soudant, J Moal, et al.
Alimentary Pharmacology & Therapeutics|October 23, 2002
A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipationJ Novick, P Miner, R Krause, et al.
Plant Physiology|May 1, 2010
Studies of a biochemical factory: tomato trichome deep expressed sequence tag sequencing and proteomicsAnthony L Schilmiller, Dennis P Miner, Matthew Larson, et al.
JAMA|July 26, 1985
Nosocomial Legionnaires' disease. Epidemiologic demonstration of cooling towers as a sourceP L Garbe, B J Davis, J S Weisfeld, et al.
Aquatic Toxicology (Amsterdam, Netherlands)|April 14, 2018
Bioactive extracellular compounds produced by the dinoflagellate Alexandrium minutum are highly detrimental for oystersJ Castrec, P Soudant, L Payton, et al.
Alimentary Pharmacology & Therapeutics|February 20, 2015
Randomised clinical trial: the 5-HT4 agonist revexepride in patients with gastro-oesophageal reflux disease who have persistent symptoms despite PPI therapyN J Shaheen, J Adler, S Dedrie, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Delaware Journal of Public Health|May 27, 2022
Characteristics and Outcomes of SARS-CoV-2 Infection Among Adults Living With HIV In Delaware:: The Story of a Syndemic During the First 12 Months of the SARS-CoV-2 PandemicAdam K Skrzynski, Brooke L Darmstadter, , et al.
Proceedings of the National Academy of Sciences of the United States of America|April 1, 1971
Isolation of transducing particles of phi-80 bacteriophage that carry different regions of the Escherichia coli genomeR Press, N Glansdorff, P Miner, et al.
Lipids|December 7, 2005
Techniques for delivery of arachidonic acid to Pacific oyster, Crassostrea gigas, spatC Seguineau, P Soudant, J Moal, et al.
Alimentary Pharmacology & Therapeutics|October 23, 2002
A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipationJ Novick, P Miner, R Krause, et al.
Plant Physiology|May 1, 2010
Studies of a biochemical factory: tomato trichome deep expressed sequence tag sequencing and proteomicsAnthony L Schilmiller, Dennis P Miner, Matthew Larson, et al.
JAMA|July 26, 1985
Nosocomial Legionnaires' disease. Epidemiologic demonstration of cooling towers as a sourceP L Garbe, B J Davis, J S Weisfeld, et al.
Aquatic Toxicology (Amsterdam, Netherlands)|April 14, 2018
Bioactive extracellular compounds produced by the dinoflagellate Alexandrium minutum are highly detrimental for oystersJ Castrec, P Soudant, L Payton, et al.
Alimentary Pharmacology & Therapeutics|February 20, 2015
Randomised clinical trial: the 5-HT4 agonist revexepride in patients with gastro-oesophageal reflux disease who have persistent symptoms despite PPI therapyN J Shaheen, J Adler, S Dedrie, et al.
Pageof 2